The CJC-1295 Story: 2006 to 2026 | Ordinary Peptides

The CJC-1295 Story: 2006 to 2026 | Ordinary Peptides
Reading Time: 17 mins
Wellness & Industry Pharmaceutical History Regulation Business
Investigative Business / Medical History

The 2006 Argentina Trial Death That Killed CJC-1295's Pharmaceutical Future and Created a Wellness Industry

How one patient's death in a Buenos Aires Phase II trial ended mainstream drug development for what became, two decades later, the most prescribed peptide combination in wellness medicine.
2026 · By the Ordinary Peptides Research Team

An Argentina Study Site, July 2006

On July 13, 2006, at a study site in Argentina, an HIV-positive man received his eleventh weekly injection of an experimental peptide drug called CJC-1295. He had been enrolled in a Phase II clinical trial sponsored by ConjuChem Biotechnologies, a Montreal-based company that believed it had developed a once-weekly treatment for HIV-associated lipodystrophy. About two hours after the injection, the patient complained of chest discomfort. An ECG confirmed an acute myocardial infarction. He died approximately one hour after that. Four days later, on July 17, 2006, ConjuChem halted the trial. The trial had been substantial. NCT00267527 was a multicenter, randomized, placebo-controlled, double-blind Phase II study with 192 enrolled participants across multiple sites in North and South America. Patients had been randomized to one of two escalating-dose CJC-1295 arms or placebo, with once-weekly subcutaneous injections over twelve weeks plus a six-week follow-up. Phase I results, published earlier that year in the Journal of Clinical Endocrinology & Metabolism, had been striking enough to make CJC-1295 one of the more closely watched compounds in growth-hormone-axis drug development. ConjuChem subsequently published its findings of the death investigation. The attending physician concluded that the most likely explanation was pre-existing asymptomatic coronary artery disease with plaque rupture and occlusion. The physician's report stated the event was "unrelated to treatment with CJC-1295." There was no evidence of cardiotoxic effects in any prior preclinical or clinical study of the drug. ConjuChem nevertheless terminated development as a precaution. No sponsor has resumed clinical development of CJC-1295 since. Today, twenty years later, the same molecular family (CJC-1295 paired with ipamorelin) is the most prescribed peptide combination in modern wellness medicine. Hundreds of telehealth platforms offer it. Thousands of med spas administer it. The U.S. wellness peptide market built around it is conservatively estimated in the hundreds of millions of dollars annually. The single Phase II trial that would have validated or rejected CJC-1295 for human therapeutic use never resumed, and what the wellness industry sells today operates entirely outside the regulatory pathway that the 2006 trial would have created. For the chemistry and current evidence on CJC-1295 No DAC and ipamorelin as research compounds, the dedicated reference page covers the science. This article is about the history that made the wellness industry possible.
A note before going further Nothing in this article is medical advice. CJC-1295 and ipamorelin are research compounds and are not FDA-approved for any human therapeutic use. The patient who died in 2006 was a real person, and the historical record (drawn from ConjuChem's corporate disclosures and contemporaneous medical reporting) is treated here with appropriate care. For chemistry, regulatory status, and current research data, see the linked product page.

ConjuChem and the DAC Bet

To understand what was lost in 2006, you have to understand what ConjuChem was trying to build. Founded in Montreal in the late 1990s, ConjuChem Biotechnologies had developed a platform technology called the Drug Affinity Complex, or DAC. The technology was a chemical modification that allowed peptides to bind to albumin (a long-lived plasma protein) and thereby acquire albumin's much longer half-life. Peptides as a drug class had a chronic problem: they typically degraded in the bloodstream within minutes, requiring daily or twice-daily injection schedules that were burdensome for patients and commercially difficult. DAC technology, in principle, could turn a peptide that needed to be injected daily into one that needed to be injected weekly. For chronic indications, the implications were enormous. CJC-1295 DAC was the lead candidate. It was a modified version of growth hormone-releasing hormone, designed to stimulate endogenous growth hormone secretion the way the natural hormone did, but with an albumin tether that extended its half-life from minutes to roughly six to eight days. Phase I results published in JCEM in 2006 by Teichman and colleagues showed that a single subcutaneous injection in healthy adults could elevate plasma growth hormone two- to ten-fold for six days or longer, and IGF-1 levels for up to eleven days. With repeat dosing, IGF-1 elevation could be sustained for nearly a month. For a peptide drug class historically constrained by short-acting pharmacokinetics, this was unprecedented data. The Phase II indication ConjuChem chose was HIV-associated lipodystrophy, a metabolic side effect of long-term antiretroviral therapy that produces abnormal fat distribution and significant patient morbidity. The choice was strategic. A competing GHRH analog from another Canadian biotech, Theratechnologies, had been pursuing the same indication on a once-daily injection schedule and was further along in development. If ConjuChem could demonstrate that a once-weekly schedule worked, the commercial differentiation against Theratechnologies' product would be substantial. The trial that began enrolling in late 2005 and completed enrollment in mid-2006 was supposed to be the data package that took CJC-1295 DAC into Phase III. It never got there.

After the Halt: 2006 to 2010

ConjuChem's investigation, published as a corporate disclosure later in 2006, attempted to make the case that the patient's death had been unrelated to study treatment. The argument was internally consistent. There were no cardiotoxic signals in the preclinical record. There were no comparable adverse events in the Phase I program or in the rest of the Phase II cohort. The attending physician's exoneration of the drug was unambiguous. By any narrow scientific standard, the case for resuming the trial was defensible. The case for not resuming was commercial. The death had been reported in trade and patient-advocacy press. Anti-doping observers had noticed the compound. Investors had absorbed a public-relations event that no biotech wants. Even with a clean attribution, the optics of restarting a Phase II program after a fatal cardiovascular event in an HIV patient (already a population with elevated cardiovascular risk on antiretroviral therapy) were difficult. ConjuChem's stock had been under pressure since the halt. The company's broader strategic situation was not strong enough to absorb additional risk on this specific program. In late 2006, ConjuChem also halted a separate DAC program in diabetes. By 2007, the company had reorganized away from the DAC platform entirely. The company itself dissolved in 2009, three years after the Argentina trial halt. The CJC-1295 program effectively died with it. There is a counterfactual worth pausing on. Theratechnologies' parallel GHRH analog, tesamorelin, continued through Phase III and was approved by the FDA on November 10, 2010, under NDA 22-505 for HIV-associated lipodystrophy. Egrifta, as the drug was branded, became the first and remains the only FDA-approved treatment for that indication. Theratechnologies had built almost the same drug, for the same indication, with similar regulatory strategy, and arrived at a different outcome. CJC-1295 had a half-life advantage and arguably more striking Phase I PK data. Theratechnologies had a Data and Safety Monitoring Board that recommended its trial continue, no patient deaths in the relevant cohort, and a sponsor with the financial depth to keep going. The molecule that survived to approval was not necessarily the better-performing molecule. It was the one whose program did not encounter a fatal event in 2006. After 2010, the commercial case for revisiting CJC-1295 collapsed. Tesamorelin had taken the approved-drug position in HIV lipodystrophy. The underlying GHRH-analog chemistry was in the public domain, so a generic-style entry by a new sponsor would have to find a different indication, finance a fresh Phase II and Phase III program, and somehow work around the historical record. No one did.

The Seventeen-Year Silence (2006 to 2023)

Between 2006 and 2023, the formal clinical record on CJC-1295 was almost completely blank. Zero registered Phase II or Phase III trials. No major pharmaceutical sponsor at any stage. A handful of academic papers continued to cite the 2006 Phase I PK data as a reference point. No published human pharmacokinetic data was ever generated for the No-DAC version of the molecule, which is the form the wellness industry eventually settled on. Outside the formal clinical record, something different happened. By 2008, biohacker forums and early longevity-focused clinics had discovered the No-DAC variant of CJC-1295, also referred to as Modified GRF(1-29). The "No DAC" qualifier mattered because it solved two problems at once. The DAC version had carried the cardiovascular signal (real or perceived) from the Argentina trial. The No-DAC version, with a half-life of roughly thirty minutes, produced a more pulsatile pattern of growth hormone release that the wellness community framed as "more natural." It also required daily injections, which paradoxically became a marketing feature: practitioners could describe the protocol as more controllable and finer-tuned than the once-weekly DAC alternative. Around the same time, ipamorelin, a synthetic pentapeptide growth hormone secretagogue developed in the 1990s by Novo Nordisk and abandoned for clinical development around the early 2000s, became available on the research-peptide market. Practitioners began co-formulating CJC-1295 No DAC with ipamorelin. The marketing message was straightforward: two complementary mechanisms (a GHRH analog and a ghrelin-receptor agonist) producing what the wellness literature began to describe as "synergistic" growth hormone release. Whether the synergy claim was supported by controlled human data was, then and now, a separate question. We have written elsewhere about how the marketing playbook for combinations like this gets built; the CJC-1295 / ipamorelin stack is one of the most successful examples in the category. By the late 2010s, compounding pharmacies including Empower, Olympia, and several regional players were preparing CJC-1295 / ipamorelin combination injections for thousands of practitioner clients. Anti-aging conferences (A4M and similar) ran practitioner-education programs. The 2018-to-2022 telehealth boom accelerated everything. By 2023, industry estimates put the U.S. CJC-1295 / ipamorelin market in the range of three to five hundred million dollars annually.
A worth-pausing-on detail By 2022, hundreds of thousands of Americans were receiving regular subcutaneous injections of a peptide combination that had collectively zero published controlled human trials. The 2006 Argentina trial halt had created a regulatory vacuum, and a multi-hundred-million-dollar wellness industry had grown comfortably inside it. There was no Phase II for the No-DAC variant. There was no Phase III for the combination. There were preclinical data, the 2006 Teichman PK paper on the DAC version, and accumulated practitioner experience. That was the evidence base.

2023 to 2024: The Regulatory Pushback

In September 2023, the FDA placed both CJC-1295 and ipamorelin on its 503A Category 2 list, alongside roughly seventeen other peptide compounds the agency had determined raised "significant safety risks" in compounded form. The reasoning the agency offered was procedural and substantive at once: insufficient formal human safety data, no IND-cleared trials in current use cases, and no published controlled efficacy data in the indications for which the substances were being compounded. Compounding pharmacies, which had been the regulated supply channel for the wellness peptide industry, were now legally barred from preparing the combination. The industry responded along several axes. A wellness clinic chain (Evexias) sued the FDA in late 2023, arguing the classification process had been procedurally flawed. The lawsuit produced a partial settlement in 2024 in which the FDA agreed to convene the Pharmacy Compounding Advisory Committee for formal review of several of the peptides, including ipamorelin and CJC-1295. On September 20, 2024, FDA published notice that five peptides (AOD-9604, CJC-1295, ipamorelin acetate, thymosin alpha-1, and Selank acetate) were being removed from Category 2 because their original nominators had withdrawn nominations; the removal took effect September 27, 2024. The PCAC then met to evaluate the substances on their merits. The October 29, 2024 meeting covered ipamorelin (acetate and free base), ibutamoren mesylate, L-theanine, and kisspeptin-10. The December 4, 2024 meeting covered CJC-1295, thymosin alpha-1 (acetate and free base), and AOD-9604. The committee's votes were the most consequential regulatory event in this molecule's history since 2006. The PCAC voted against adding ipamorelin to the 503A bulks list. It voted against adding CJC-1295. It voted against most of the others. The reasons given by committee members who voted "no" centered on the same point: the available human safety and efficacy evidence was not sufficient to support compounding for the proposed indications. The largest published clinical trial on ipamorelin (Beck et al. 2014, in postoperative ileus) had failed its primary endpoint. The clinical record on CJC-1295 was thinner still. PCAC votes are non-binding recommendations to the FDA, not final regulatory decisions. The agency typically follows them, however, and ipamorelin was placed back on Category 2 status in the months following the October vote. The wellness industry's compounding-pharmacy supply chain, which had briefly reopened after the September 2024 procedural withdrawal, closed again. Many telehealth platforms quietly migrated to research-only labeling. Some clinics moved to overseas-sourced product. The market did not shrink. It routed around the regulation, the same pattern documented in the GLOW case.

2026: The RFK Jr. Reset

In February 2026, HHS Secretary Robert F. Kennedy Jr. went on the Joe Rogan Experience and announced his intent to reverse the Category 2 designations on most of the peptides the FDA had restricted in 2023. He framed the original FDA decision as an overreach. He said he expected approximately fourteen of the nineteen peptides to be moved back to Category 1, where compounding is permitted under physician prescription. In April 2026, the procedural follow-through began. Twelve peptides came off Category 2 because their nominators withdrew (or re-withdrew) their nominations. The FDA simultaneously announced that the Pharmacy Compounding Advisory Committee would meet on July 23-24, 2026 to discuss formal addition of these substances to the 503A bulks list, and again before the end of February 2027 for additional substances. The CJC-1295 / ipamorelin path through this 2026 reset is, however, structurally different from the path of compounds like BPC-157 or TB-500. Those compounds had never received an explicit PCAC vote against them. Ipamorelin and CJC-1295 had: October 2024 and December 2024 respectively. Reversing those votes is harder than reversing a procedural placement. New PCAC reviews would, in principle, require new evidence. New evidence would, in principle, require new clinical trials. New clinical trials would cost meaningful money and require a sponsor with both capital and a clinical strategy. The structural problem that RFK Jr.'s political alignment cannot directly fix is the underlying drug-development economics. The 2006 Argentina death is a historical fact. No sponsor has Phase III data. No FDA approval pathway currently exists for either compound for the indications wellness medicine actually uses them for. Reclassification to Category 1 would only enable compounding under physician prescription; it would not produce drug approval. True drug approval for an off-the-shelf wellness indication (general anti-aging, body composition, sleep quality) would require a sponsor to run a fresh Phase II and Phase III program, at an estimated cost of fifty to one hundred million dollars per program. The patent economics still discourage that investment because the underlying sequences are in the public domain. No pharma sponsor has stepped forward in the twenty years since 2006. There is no obvious reason to expect one in 2026. The likely 2026-to-2027 outcome is a slightly redrawn version of the same regulatory limbo. Compounding pharmacies may regain partial access. Telehealth platforms may scale back up under prescription models. Med spas may reactivate "GH peptide" promotional emails timed to whatever the July PCAC meeting produces. But the 2006 Argentina death created a pharmacological orphan, and pharmacological orphans tend to remain orphans.

Where This Goes Next

Three things to watch over the next eighteen months. The PCAC ipamorelin question redux. The October 2024 vote was binding only for the procedural status that was current at the time. A new submission with new evidence could trigger a fresh review. Whether that happens depends on whether anyone funds the new evidence. The wellness industry has the commercial volume to in principle finance a serious clinical trial, but the industry's structure (fragmented across thousands of clinics and compounding pharmacies, no central commercial sponsor) makes that kind of pooled investment unusual. Watch for any single telehealth platform of size announcing a registered Phase II program; that would be the signal that the structural problem might actually be addressed. Tesamorelin off-label as the alternative trajectory. Egrifta is FDA-approved. Egrifta WR, the newer F8 formulation Theratechnologies launched in 2025, is approved with simpler reconstitution. Off-label prescribing of tesamorelin in non-HIV wellness contexts is rising, slowly. Cost remains an issue: the approved drug runs an order of magnitude higher than compounded CJC-1295 / ipamorelin in monthly cost. But it has legitimate FDA approval, real safety data, and a regulated supply chain. A plausible 2027-to-2028 trajectory has telehealth platforms shifting their GH-axis offerings toward tesamorelin off-label use. Lower volumes, higher per-patient revenue, dramatically less regulatory exposure. The economics could work if the platforms are willing to accept smaller customer bases. Research-only enforcement under HHS. Kennedy's stated position is that he wants to "shift demand away from the black market." The intended interpretation is that compounding-pharmacy access should expand. The unintended (or intended) implication is that enforcement against research-only sellers might tighten, which would reduce the third-channel volume that has absorbed market growth since 2023. The historical pattern is that enforcement resources at FDA are limited and that aggressive action against research-chemical vendors is rare. The current administration has signaled different priorities. Whether action follows the rhetoric is the open question of the next eighteen months.

The Bottom Line

CJC-1295 is a case study in how a clinical setback becomes a commercial opportunity. The 2006 Argentina death halted ConjuChem's drug program. It did not halt the molecule. Twenty years later, an entire wellness industry depends on the absence of FDA approval, because if CJC-1295 had been approved as a drug in 2010 alongside tesamorelin, the compounded research-peptide market in its current form would not exist. Wellness medicine, in the GH-axis space, is built precisely in the regulatory gap that the Argentina trial created. Whether that gap closes in 2026, widens, or remains stable depends on factors mostly unrelated to the underlying biology: regulatory politics, enforcement priorities, sponsor economics, telehealth platform decisions. The molecule itself sits where it has sat since July 2006. Pharmacologically interesting. Commercially active. Scientifically incomplete. The wellness industry has decided that is good enough for the use cases it has built around it. The FDA, for now, has decided otherwise. The reconciliation between those two positions is the next chapter of a story that began with one patient, in one Argentina clinic, in the summer of 2006.
Editorial Disclosure Ordinary Peptides supplies research-grade CJC-1295 (No DAC) and ipamorelin as laboratory compounds. This article is editorial coverage of the regulatory and industry history of these compounds, not promotion of any specific product. For the chemistry, mechanism, evidence base, and current regulatory status of CJC-1295 and ipamorelin themselves, see the linked reference page. For the broader category of GH-axis research peptides, see the regenerative peptides section.
Sources & Further Reading
  1. Aidsmap. "Lipodystrophy study halted after patient death." July 2006. aidsmap.com
  2. ClinicalTrials.gov. NCT00267527. "A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Phase 2 Study to Evaluate the Efficacy and Safety of CJC 1295." clinicaltrials.gov
  3. Teichman SL, Neale A, Lawrence B, et al. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults." J Clin Endocrinol Metab. 2006;91(3):799-805. PMID 16352683.
  4. Ionescu M, Frohman LA. "Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog." J Clin Endocrinol Metab. 2006;91(12):4792-4797.
  5. FDA. Center for Drug Evaluation and Research. "Egrifta (tesamorelin) Approval Summary." NDA 22-505. November 10, 2010. accessdata.fda.gov
  6. Theratechnologies. "EGRIFTA WR (tesamorelin F8) FDA Approval Press Release." March 25, 2025.
  7. FDA. "October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee." fda.gov
  8. FDA PCAC Meeting Minutes (October 29, 2024 and December 4, 2024). fda.gov
  9. Alliance for Pharmacy Compounding. "PCAC votes against four nominated bulk drug substances." November 2024. a4pc.org
  10. Lexology. "FDA removes certain peptide bulk drug substances from Category 2 of interim 503A bulks list." October 2024. lexology.com
  11. Inc. Magazine. Sara Shikhman. "Peptides Are Booming in Wellness Clinics." November 14, 2025. inc.com
  12. Glossy. "Injectable peptide therapy went mainstream in 2025." January 2026. glossy.co
  13. STAT News First Opinion. "RFK Jr.'s peptide push could unleash risky drugs." April 29, 2026. statnews.com
  14. Wikipedia. "CJC-1295." en.wikipedia.org
  15. WADA Prohibited List 2026, S2 (Peptide Hormones, Growth Factors, and Related Substances). wada-ama.org
Editorial Desk · All external links open in a new tab · 2026